Havana: Within a few days of starting phase III of clinical trials with 42,600 volunteers, Soberana 02 vaccine has been latest news domestically and internationally, Prensa Latina reports.
‘Hopeful vaccine’, ‘safe technology’, ‘the first vaccine candidate in Latin America’ and ‘extraordinary breakthrough’ are just some phrases on several articles on The New York Times, Business Insider, EuroNews and the BBC.
Soberana 02 is a ‘global trending’ because it is innovative. It is the only candidate for the conjugate vaccine platform in the world … Soon … another start, Dagmar García, research director of the Finlay Vaccine Institute, tweeted.
Cuban President Miguel Díaz-Canel on Sunday highlighted the progress of the production of Soberana 02 and described it as another step towards the long-awaited immunization for Cubans.
For her part, Roselyn Martínez, deputy director of Industrial Operations of the Finlay Vaccine Institute, detailed that the biopharmaceutical industry has already produced the first batch of 150,000 Soberana 02 bulbs and also said a second batch is being produced.
Cuba, the first in Latin America to present its own Covid-19 vaccines, also has three other proposals Soberana 01 from the Finlay Institute and those prepared at the Abdala and Mambisa Center for Genetic Engineering and Biotechnology.
The director of the Institute, Vicente Vérez, explained in recent days that phase III of Soberana 02 is scheduled for next March 1 because it showed great safety in its study stages II A and II B, as well as a powerful immune response.
“It also induces long-term memory of that immune response that, in addition to producing antibodies, makes them last?, the expert said.
He also highlighted that with this product the use of a third dose with reinforcing action is evaluated in order to induce viral neutralization immune response and a trial in pediatric patients.
It is a conjugate vaccine, in which the antigen of the virus, the receptor-binding domain (RBD), is chemically bound to tetanus toxoid, it has two formulations and the second of them was highly effective in animals.
The Caribbean island, the first in Latin America to present its own vaccines against Covid-19, also has three other proposals against Covid-19, Sovereign 01 from the Finlay Institute and those prepared at the Abdala and Mambisa Center from the Genetic Engineering and Biotechnology.